Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.

Sector

Healthcare

Industry

Biotechnology

CEO

Wang, Li

Employees

Website

www.bio-heart.com

IPO Date

2021-12-23

Headquarters

Building 4, Room 302, 3rd Floor, No.590 Ruiqing Road, E. Zhangjiang Hi-Tech Park, Pudong New A, Shanghai China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.